Notice
2 Jul 2025
compliance, healthcare, regulatory, pharmaceuticals, fda, drug approval, patent extension, livdelzi
💊FDA Determines Regulatory Review Period for LIVDELZI Patent Extension
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LIVDELZI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.
Learn More